This is the first report of a detailed relationship between triazole treatment history 2 and triazole MICs for 154 Aspergillus fumigatus clinical isolates. The duration of 3 itraconazole dosage increased as the itraconazole MIC increased, and a positive 4 correlation was observed (r = 0.5700, p < 0.0001). The number of itraconazole-naïve 5 isolates dramatically decreased as the itraconazole MIC increased, particularly for MICs 6 exceeding 2 μg/ml (0.5 μg/ml vs. 2 μg/ml, p = 0.03). We also examined the relationship 7 between cumulative itraconazole usage and the MICs of other azoles. A positive 8 correlation existed between itraconazole dosage period and posaconazole MIC (r = 9 0.5237, p < 0.0001). The number of itraconazole-naïve isolates also decreased as the 10 posaconazole MIC increased, particularly for MICs exceeding 0.5 μg/ml (0.25 μg/ml vs. 11 0.5 μg/ml, p = 0.004). Conversely, the correlation coefficient obtained from the 12 scattergram of itraconazole usage and voriconazole MICs was small (r = −0
patient with chronic pulmonary aspergillosis after oral itraconazole therapy. We should 1 consider the possible appearance of azole-resistant A. fumigatus if itraconazole is used 2 for extended periods. (Epicentre Biotechnologies, Madison, WI), and 9 short tandem repeat region (2A, 2B, 1 2C, 3A, 3B, 3C, 4A, 4B, 4C) were amplified by PCR as described previously (12). The 2 repeat numbers were determined by sequencing analysis, and we compared the patterns 3 of repeat numbers. DNA sequences were determined using a BigDye Terminator version 4 1.1 cycle sequencing kit (ABI, USA) and an ABI 3100xl DNA analyzer. 5
Statistics Statistical analyses of azole usage and azole susceptibility were 6 performed using Pearson's correlation and Fisher's exact tests with Prism version 5.0 7 (GraphPad, USA). Differences were considered significant when p < 0.05. 8
9

RESULTS
10
Correlation between azole usage (duration and amount) and azole 11 susceptibility A total of 154 A. fumigatus clinical isolates obtained from 64 patients 12 were analyzed. Most of these specimens were isolated from the lungs (Table 1) . Chronic 13 pulmonary aspergillosis (included simple aspergilloma) accounted for 61% of the 14 clinical diagnoses (Table 1) . 15
The scatter plot of the itraconazole dosage period and itraconazole MICs is shown 16 in Figure 1A . Patients infected by A. fumigatus with itraconazole MICs < 2 μg/ml had 17 been treated with itraconazole for <1 year. All isolates with itraconazole MICs ≥ 4μg/ml (MF-452, MF-460, MF-468, MF-469, MF-329, and MF-357) had been exposed 1 to itraconazole for >115 days ( Table 2 ). The itraconazole dosage duration increased as 2 the itraconazole MIC increased, and the dosage duration was positively correlated with 3 the itraconazole MIC (r = 0.5700, p < 0.0001) ( Figure 1A ). The number of 4 itraconazole-naïve isolates dramatically decreased as the MIC increased, particularly for 5
MICs exceeding 2 μg/ml (0.5 μg/ml vs. 2 μg/ml, p = 0.03) ( Figure 1B ). These results 6 indicated that long-term itraconazole treatment could induce azole-resistant A. A. fumigatus was isolated after voriconazole treatment from only a few patients; 1 therefore, an analysis of the relationship between voriconazole usage histories before A. 2 fumigatus isolation and azole susceptibilities was limited. Only 10 isolates were 3 exposed to voriconazole therapy before isolation, and the average duration of the 4 therapy was 8.3 ± 6.3 days. Voriconazole exposure did not alter the susceptibility of the 5 3 triazole agents. 6
In this study, we counted the duration of azole exposure as the cumulative time of 7 treatment. A. fumigatus was not always clinically isolated from patients during therapy; 8 it was also isolated after the cessation of azole therapy. Because the selection pressure 9 on azole-resistant A. fumigatus might be the highest during the treatment, azole 10 resistance might dissipate over time after therapy. Hence, we examined the relationship 11 between the itraconazole MIC and the time from the end of itraconazole therapy to 12 isolation. Of the 154 isolates, 42 had been exposed to itraconazole therapy before 13 isolation. The time from the end of itraconazole treatment to isolation had no 14 relationship with itraconazole susceptibility (r = −0.1302, p = 0.4110) (Figure 3) . 15
Azole-resistant A. fumigatus was isolated even after azole treatment had been 16 discontinued.
patients were infected with azole-resistant A. fumigatus, and 16 isolates were obtained 1 from these patients (including susceptible isolates) ( Table 2 ). To analyze the genetic 2 relationships among these 16 isolates, a panel of nine short tandem repeats for exact and 3 high-resolution fingerprinting of A. fumigatus isolates was performed in this study. The 4 16 isolates obtained from the 5 patients were divided into 6 genotypes via microsatellite 5 typing (Table 3) . 6
Nine isolates were cultured from Patient 1 ( Table 2) . A. fumigatus isolated in 7 earlier periods was azole-susceptible, and it harbored the I266N mutation in the cyp51A 8 gene; however, later isolates showed itraconazole or posaconazole resistance and new 9 mutations such as G54E. Despite the discontinuation of itraconazole treatment, 10 azole-resistant isolates were cultured from his sputum 140 days after the end of the 11 treatment ( Table 2 ). All isolates were confirmed to be genetically homogeneous (Table  12 3). in this study was that the G54 mutation in azole-resistant isolates resulted in a resistance 17 to itraconazole and posaconazole but not to voriconazole.
The most important limitation of this study was that no data could be obtained 1 regarding the serum concentration of itraconazole during its usage. Itraconazole has a 2 relatively low bioavailability after oral administration, especially when given in capsule 3 form (33). Of the 42 isolates exposed to itraconazole before isolation, 39 had been 4 exposed to itraconazole capsules, and the remaining 3 isolates had been exposed to the 5 oral solution, which has a greater bioavailability than the capsule form (5). Most 6 patients who were administered the capsule form of itraconazole were prescribed a dose 7 of 200 mg/day, which is the approved dose in Japan. Despite the lack of a report 8 examining the presence of a mutation selection window for itraconazole by A. fumigatus, 9 both the low bioavailability and blood concentration of itraconazole in capsule form 10 might be risk factors for azole resistance. The solution form may overcome these 11 disadvantages; however, Patient 4 who was infected with posaconazole-resistant A. 12 fumigatus carrying the G54W cyp51A mutation, had been administered the itraconazole 13 oral solution at a dose of 200 mg/day for 210 days. 14 Itraconazole oral therapy is often administered long-term for the treatment of 15 chronic pulmonary aspergillosis (32). The judgment of treatment failure is still difficult; 16 therefore, we need more information to decide whether the itraconazole treatment 17 should be continued. Despite the importance of the duration of itraconazole treatmentwith respect to the induction of azole resistance, few studies have investigated the 1 relationship between azole resistance and azole exposure. Howard et al. reported that 2 the duration of azole exposure before the identification of the first resistant isolate was 3 1-30 months, and the most commonly administered azole was itraconazole (17). 4
Mortensen et al. also reported that patients with azole-resistant A. fumigatus isolates had 5 received mold-active azoles for 11.5-69.5 months before the detection of resistant 6
isolates (22). In our study, patients with azole-resistant A. fumigatus had been 7 administered itraconazole for 3.8-24.3 months. These data are similar to those described 8 above. Moreover, patients infected by A. fumigatus with itraconazole MICs < 2 μg/ml 9 had been administered itraconazole for <1 year. Clinicians should be careful of the 10 potential appearance of itraconazole-resistant isolates during long-term sequential 11 itraconazole therapy for several months to more than 1 year. 12
Recently, Camps et al. reported that median time between the last cultured 13 wild-type isolate and the first azole-resistant isolate was 4 month (range, 3 weeks to 23 14 months) (8) . In our study, time between the last isolation of azole sensitive strain and 15 first appearance of azole-resistant strain was about 10 and 7 months in patient 1 and 4, 16 respectively ( Table 2 ). These periods were longer than median time reported by CampsWe confirmed that long-term itraconazole therapy induced azole resistance in A. 1 fumigatus. Even if azole-resistant mutants were dominant during treatment, their 2 dominance could dissipate after cessation of the therapy because of the differences in 3 the growth rates of the resistant and susceptible specimens (3). However, resistant 4 isolates were still cultured 140 days after the cessation of azole therapy in Patient 1. In 5
Patients 3 and 5, the time from the end of treatment to isolation was 1223 and 435 days, 6 respectively, which might indicate the possibility of the presence of resistant isolates for 7 years after the end of azole therapy or the possibility of new infection. There were no 8 differences in the growth rate of azole-resistant and azole-susceptible A. fumigatus 9 isolates in vitro (data not shown). When patients receive long-term itraconazole therapy, 10 clinicians should aggressively culture A. fumigatus from the patients and perform 11 susceptibility tests even long after the cessation of itraconazole therapy. 12
We isolated azole-resistant A. fumigatus from clinical samples, such as sputum, 13 but we did not isolate A. fumigatus from the environment or detect a TR/L98H mutant 14 (28). It is interesting to note that the most common mechanism of resistance detected in 15 this study was G54 substitution, because the selection pressure of itraconazole induces 16 G54 mutation (13). Moreover, most resistant isolates detected in the environments 17 around the world carry the TR/L98H substitution and no other mutation such as G54substitution (10, 23). These facts suggest that different azoles select different mutations. 1
Itraconazole might selectively induce mutations such as G54 substitution, whereas some 2 azoles used in agriculture may tend to select the TR/L98H mutation. The mechanisms of 3 these differences remain to be completely elucidated. Further investigation is needed to 4 clarify these mechanisms, and this knowledge may enable us to prevent the induction of 5 the TR/L98H mutation in the environment. 6
In conclusion, this is the first report to show a detailed relationship between azole 7 usage and azole MICs for A. fumigatus. Furthermore, we confirmed the presence of 8 acquired resistance to itraconazole and posaconazole in a patient with chronic 9 pulmonary aspergillosis after consecutive oral itraconazole therapy in Japan. The 10 possibility of azole-resistant A. fumigatus should be considered during long-term 11 itraconazole therapy in patients with chronic pulmonary aspergillosis. Table1. Tashiro et al. 
